APA

Melchardt T., Hufnagl C., Magnes T., Weiss L., Hutarew G., Neureiter D., Schlattau A., Moser G., Gaggl A., Tränkenschuh W., Greil R. & Egle A. (20160629). CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer. : BMC cancer.

Chicago

Melchardt Thomas, Hufnagl Clemens, Magnes Teresa, Weiss Lukas, Hutarew Georg, Neureiter Daniel, Schlattau Alexander, Moser Gerhard, Gaggl Alexander, Tränkenschuh Wolfgang, Greil Richard and Egle Alexander. 20160629. CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer. : BMC cancer.

Harvard

Melchardt T., Hufnagl C., Magnes T., Weiss L., Hutarew G., Neureiter D., Schlattau A., Moser G., Gaggl A., Tränkenschuh W., Greil R. and Egle A. (20160629). CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer. : BMC cancer.

MLA

Melchardt Thomas, Hufnagl Clemens, Magnes Teresa, Weiss Lukas, Hutarew Georg, Neureiter Daniel, Schlattau Alexander, Moser Gerhard, Gaggl Alexander, Tränkenschuh Wolfgang, Greil Richard and Egle Alexander. CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer. : BMC cancer. 20160629.